{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:10:09Z","timestamp":1723626609855},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00108-017-0243-y","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T12:04:09Z","timestamp":1495541049000},"page":"585-597","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antikoagulation \u2013 direkte orale Antikoagulanzien"],"prefix":"10.1007","volume":"58","author":[{"given":"B.","family":"Kemkes-Matthes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","volume":"141","author":"D Wardrop","year":"2008","unstructured":"Wardrop D, Keeling D (2008) The story of the discovery of heparin and warfarin. Br J Haematol 141:757\u2013763","journal-title":"Br J Haematol"},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL et al (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J\u00a0Thromb Haemost 14:1308\u20131313","journal-title":"J Thromb Haemost"},{"issue":"4","key":"243_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.116.025923","volume":"135","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL (2016) O PIONEERs! \u2013 The beginning of the end of full dose triple therapy with warfarin? Circulation 135(4):334\u2013337","journal-title":"Circulation"},{"key":"243_CR4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0037-1618984","volume":"7","author":"H Schinzel","year":"2016","unstructured":"Schinzel H (2016) Heparine \u2013 DOAKs \u2013 VKA. Pro und Contra unter besonderer Ber\u00fccksichtigung von Tumorpatienten. Onkol Welt 7:206\u2013216","journal-title":"Onkol Welt"},{"key":"243_CR5","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2013-04-460162","volume":"122","author":"AYY Lee","year":"2013","unstructured":"Lee AYY, Peterson EA (2013) Treatment of cancer-associated thrombosis. Blood 122:2310\u20132317","journal-title":"Blood"},{"key":"243_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.13810","volume":"172","author":"BJ Dale","year":"2016","unstructured":"Dale BJ, Chan NC, Eikelboom JW (2016) Laboratory measurement of the direct oral anticoagulants. Br J Haematol 172:315\u2013336","journal-title":"Br J Haematol"},{"key":"243_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH14-02-0161","volume":"113","author":"M Blerk Van","year":"2015","unstructured":"Van Blerk M, Bailleul E, Chatelain B et\u00a0al (2015) Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 113:154\u2013164","journal-title":"Thromb Haemost"},{"key":"243_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1160\/TH13-05-0431","volume":"111","author":"G Dickneite","year":"2014","unstructured":"Dickneite G, Hoffman M (2014) Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 111:189\u2013198","journal-title":"Thromb Haemost"},{"key":"243_CR9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","volume":"124","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124:955\u2013962","journal-title":"Blood"},{"key":"243_CR10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","volume":"14","author":"JH Levy","year":"2016","unstructured":"Levy JH, Ageno W, Chan NC et\u00a0al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J\u00a0Thromb Haemost 14:623\u2013627","journal-title":"J Thromb Haemost"},{"key":"243_CR11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","volume":"117","author":"JE Ansell","year":"2017","unstructured":"Ansell JE, Bakhru SH, Laulicht BE et al (2017) Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 117:238\u2013245","journal-title":"Thromb Haemost"},{"key":"243_CR12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJJ, Eikelboom JW et\u00a0al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N\u00a0Engl J Med 375:1131\u20131141","journal-title":"N Engl J Med"},{"key":"243_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CVJ Pollack","year":"2015","unstructured":"Pollack CVJ, Reilly PA, Eikelboom J et\u00a0al (2015) Idarucizumab for dabigatran reversal. N\u00a0Engl J Med 373:511\u2013520","journal-title":"N Engl J Med"},{"key":"243_CR14","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/STROKEAHA.116.013550","volume":"47","author":"J Berrouschot","year":"2016","unstructured":"Berrouschot J, Stoll A, Hogh T et al (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a\u00a0stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936\u20131938","journal-title":"Stroke"},{"key":"243_CR15","first-page":"575","volume":"113","author":"M Maegele","year":"2016","unstructured":"Maegele M, Grottke O, Sch\u00f6chl H et\u00a0al (2016) Direkte orale Antikoagulanzien in der traumatologischen Notaufnahme. Dtsch Arztebl Int 113:575\u2013582","journal-title":"Dtsch Arztebl Int"},{"key":"243_CR16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T Der Hulle Van","year":"2014","unstructured":"Van Der Hulle T, Kooiman J, Den Exter PL et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin\u00a0K antagonists in the treatment of acute symptomatic venous thromboembolism: a\u00a0systematic review and meta-analysis. J\u00a0Thromb Haemost 12:320\u2013328","journal-title":"J Thromb Haemost"},{"key":"243_CR17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a\u00a0meta-analysis of randomised trials. Lancet 383:955\u2013962","journal-title":"Lancet"},{"key":"243_CR18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jth.12486","volume":"12","author":"JC Lega","year":"2014","unstructured":"Lega JC, Bertoletti L, Gremillet C et\u00a0al (2014) Consistency of safety profile of new oral anticoagulants in patients with renal failure. J\u00a0Thromb Haemost 12:337\u2013343","journal-title":"J Thromb Haemost"},{"key":"243_CR19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","volume":"116","author":"GYH Lip","year":"2016","unstructured":"Lip GYH, Keshishian A, Kamble S et al (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116:975\u2013986","journal-title":"Thromb Haemost"},{"key":"243_CR20","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","volume":"3","author":"W Ageno","year":"2015","unstructured":"Ageno W, Mantovani LG, Haas S et al (2015) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3:e12\u2013e21","journal-title":"Lancet Haematol"},{"key":"243_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv466","author":"AJ Camm","year":"2015","unstructured":"Camm AJ, Amarenco P, Haas S et al (2015) XANTUS: a\u00a0real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. doi: 10.1093\/eurheartj\/ehv466","journal-title":"Eur. Heart J."},{"key":"243_CR22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1160\/TH16-03-0203","volume":"116","author":"J Carmo","year":"2016","unstructured":"Carmo J, Moscoso Costa F, Ferreira J et al (2016) Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 116:754\u2013763","journal-title":"Thromb Haemost"},{"key":"243_CR23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1160\/TH15-11-0902","volume":"115","author":"J Beyer-Westendorf","year":"2016","unstructured":"Beyer-Westendorf J, Michalski F, Tittl L et al (2016) Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. Thromb Haemost 115:1234\u20131236","journal-title":"Thromb Haemost"},{"key":"243_CR24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1160\/TH16-04-0305","volume":"116","author":"J Beyer-Westendorf","year":"2016","unstructured":"Beyer-Westendorf J, Michalski F, Tittl L et al (2016) Pregnancy outcome in patients exposed to direct oral anticoagulants \u2013 and the challenge of event reporting. Thromb Haemost 116:651\u2013658","journal-title":"Thromb Haemost"},{"key":"243_CR25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1160\/TH15-04-0275","volume":"116","author":"JML Halton","year":"2016","unstructured":"Halton JML, Lehr T, Cronin L et al (2016) Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost 116:461\u2013471","journal-title":"Thromb Haemost"},{"issue":"Suppl.1","key":"243_CR26","first-page":"1","volume":"45","author":"V Hach-Wunderle","year":"2016","unstructured":"Hach-Wunderle V (2016) Interdisziplin\u00e4re S2k-Leitlinie: Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Vasa 45(Suppl.1):1\u201348","journal-title":"Vasa"},{"key":"243_CR27","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu243","volume":"35","author":"SV Konstantinides","year":"2014","unstructured":"Konstantinides SV, Torbicki A, Agnelli G et\u00a0al (2014) ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033\u20133073","journal-title":"Eur. Heart J."},{"key":"243_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J et\u00a0al (2016) Antithrombotic therapy for vte disease: Chest guideline and expert panel report. Chest 149:315\u2013352","journal-title":"Chest"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0243-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T23:45:44Z","timestamp":1569368744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0243-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0243-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}